The Relationship Between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease.
作者信息
Byrne Christopher D
机构信息
Professor of Endocrinology and Metabolism Faculty of Medicine University of Southampton Southampton General Hospital Southampton, United Kingdom.
出版信息
Gastroenterol Hepatol (N Y). 2022 Sep;18(9):549-552.
Abstract
摘要
相似文献
1
The Relationship Between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease.非酒精性脂肪性肝病与慢性肾脏病之间的关系
Gastroenterol Hepatol (N Y). 2022 Sep;18(9):549-552.
2
Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease.慢性肾脏病与非酒精性脂肪性肝病患者的死亡率增加独立相关。
Liver Int. 2019 Feb;39(2):342-352. doi: 10.1111/liv.13992. Epub 2018 Dec 4.
3
CKD and nonalcoholic fatty liver disease.慢性肾脏病与非酒精性脂肪性肝病。
Am J Kidney Dis. 2014 Oct;64(4):638-52. doi: 10.1053/j.ajkd.2014.05.019. Epub 2014 Jul 30.
4
Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease.非酒精性脂肪性肝病相关慢性肾脏病。
Can J Gastroenterol Hepatol. 2020 Dec 29;2020:6630296. doi: 10.1155/2020/6630296. eCollection 2020.
5
Relationship between nonalcoholic fatty liver disease and chronic kidney disease could start in childhood.非酒精性脂肪肝疾病与慢性肾脏病之间的关系可能从儿童期就开始了。
World J Gastroenterol. 2021 Sep 14;27(34):5793-5795. doi: 10.3748/wjg.v27.i34.5793.
6
A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C.非酒精性脂肪性肝病与慢性丙型肝炎纤维化潜能的比较。
Hum Pathol. 2010 Aug;41(8):1178-85. doi: 10.1016/j.humpath.2009.10.025. Epub 2010 Apr 22.
7
The Relationship between Intestinal Motility and Interstitial Cells of Cajal in Nonalcoholic Fatty Liver Mice.非酒精性脂肪肝小鼠肠道运动与 Cajal 间质细胞的关系
Hepat Mon. 2013 Oct 1;13(10):e13674. doi: 10.5812/hepatmon.13674. eCollection 2013.
8
End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program.终末期非酒精性脂肪性肝病：肝移植供体肝活检测定中对隐匿性肝硬化与非酒精性脂肪性肝病肝组织形态学特征及其关系的评价
Hum Pathol. 2010 Mar;41(3):425-30. doi: 10.1016/j.humpath.2009.06.021. Epub 2009 Dec 1.
9
Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.非酒精性脂肪性肝病（NAFLD）——腹膜透析患者的一种新的心血管危险因素。
Perit Dial Int. 2016 Jul-Aug;36(4):427-32. doi: 10.3747/pdi.2014.00223. Epub 2015 Oct 16.
10
Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis.牙周病相关的非酒精性脂肪性肝病和非酒精性脂肪性肝炎：口腔-肝脏轴的一个新兴概念。
Periodontol 2000. 2021 Oct;87(1):204-240. doi: 10.1111/prd.12387.
引用本文的文献
1
Identification of crosstalk genes relating to ECM-receptor interaction genes in MASH and DN using bioinformatics and machine learning.使用生物信息学和机器学习鉴定 MASH 和 DN 中与 ECM-受体相互作用基因相关的串扰基因。
J Cell Mol Med. 2024 Mar;28(6):e18156. doi: 10.1111/jcmm.18156.
本文引用的文献
1
Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people?是时候考虑采用整体方法来治疗肥胖年轻人的非酒精性脂肪性肝病了吗？
Gut. 2023 Jul;72(7):1238-1239. doi: 10.1136/gutjnl-2022-328316. Epub 2022 Aug 9.
2
Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.2022 年班廷纪念讲座：“2 型糖尿病与非酒精性脂肪性肝病：罪恶的伙伴”。
Diabet Med. 2022 Oct;39(10):e14912. doi: 10.1111/dme.14912. Epub 2022 Jul 20.
3
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.过氧化物酶体增殖物激活受体激动剂、胰高血糖素样肽-1受体激动剂或钠-葡萄糖协同转运蛋白2抑制剂治疗非酒精性脂肪性肝病的疗效：一项系统评价
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):367-378. doi: 10.1016/S2468-1253(21)00261-2. Epub 2022 Jan 12.
4
Association of metabolic dysfunction-associated fatty liver disease with kidney disease.代谢功能障碍相关脂肪性肝病与肾脏疾病的关联
Nat Rev Nephrol. 2022 Apr;18(4):259-268. doi: 10.1038/s41581-021-00519-y. Epub 2022 Jan 10.
5
Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications.非酒精性脂肪性肝病相关的心血管疾病及其他心脏并发症风险。
Diabetes Obes Metab. 2022 Feb;24 Suppl 2:28-43. doi: 10.1111/dom.14484. Epub 2021 Aug 13.
6
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.非酒精性脂肪性肝病：一种需要多学科和整体方法的多系统疾病。
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):578-588. doi: 10.1016/S2468-1253(21)00020-0. Epub 2021 May 4.
7
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.非酒精性脂肪性肝病与新发慢性肾脏病风险：一项更新的荟萃分析。
Gut. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082. Epub 2020 Dec 10.
8
NAFLD as a driver of chronic kidney disease.非酒精性脂肪性肝病作为慢性肾脏病的一个驱动因素。
J Hepatol. 2020 Apr;72(4):785-801. doi: 10.1016/j.jhep.2020.01.013. Epub 2020 Feb 12.
9
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.非酒精性脂肪性肝病增加了慢性肾脏病发病的风险：系统评价和荟萃分析。
Metabolism. 2018 Feb;79:64-76. doi: 10.1016/j.metabol.2017.11.003. Epub 2017 Nov 11.
10
The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?非酒精性脂肪性肝炎（NASH）与慢性肾脏病共存会增加心血管风险：是否有共同的治疗选择？
Curr Vasc Pharmacol. 2018;16(3):254-268. doi: 10.2174/1570161115666170621081638.
Zotero 插件